...
SDPA Fall 2018 | Product Theater | Are Your Topical Patients Systemic-Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis
November 3, 2018

At the first product theater on day 3 of the 16th Annual Fall Dermatology Conference, Dr. Firas Hougeir shared his extensive knowledge and experience in the treatment of patients with psoriasis with his lecture entitled Are Your Topical Patients Systemic-Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis. Dr. Hougeir started his lecture …

...
Diet and Psoriasis: Some Recommendations
September 12, 2018

Patients with psoriasis report that the condition affects many aspects of their overall health and often alter their diet to try to combat some psoriasis symptoms. A recent review study looked at the evidence base for dietary interventions for psoriasis to answer some key questions about the role of diet in psoriatic diseases. The review …

...
Summer 2018 | Live Blog | Product Theater | A Closer Look at Taltz
June 30, 2018

The first product theater on Day 3 of the SDPA Annual Summer Conference was “A Closer Look at Taltz” presented by Dr. Andrew Blauvelt. Taltz is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for adults with active psoriatic arthritis. Dr. Blauvelt reports that in …

...
Summer 2018 | Live Blog | Product Theater | Are Your Topical Patients Systemic Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis
June 29, 2018

The second product theater on day 2 of the SDPA Annual Summer Conference presented by Robert Casquejo, PA-C discussed Otezla as a treatment for adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy and systemic therapy. Otezla is an oral medication that inhibits phosphodiesterase 4 …

...
Summer 2018 | Live Blog | Product Theater | More Than Skin Deep with Cosentyx (secukinumab): Proven Effective for Psoriatic Arthritis
June 28, 2018

Andrea Nguyen, MS, PA-C presented the second product theater on the first day of the SDPA Annual Summer Conference. She discussed Cosentyx, the first and only fully human Il-17A antagonist approved for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. Cosentyx is also indicated for the treatment of ankylosing spondylitis. Ms. Nguyen …